Gotowa bibliografia na temat „Kathleen Murray”

Stoekl, Allan. 2021. The Three Sustainabilities: Energy, Economy, Time. Minneapolis, MN: University of Minnesota Press. 307 pp. ISBN 978-1517908188.Carrasco, Anita. 2020. Embracing the Anaconda: A Chronicle of Atacameño Life and Mining in the Andes. Lanham, MD: Lexington Books. 182 pp. ISBN 978-1498575157.Sullivan, Kathleen M., and James H. McDonald, eds. 2020. Public Lands in the Western US: Place and Politics in the Clash between Public and Private. 226 pp. Lanham, MD: Lexington Books. ISBN 978-1793637062.Hirsch, Shana Lee. 2020. Anticipating Future Environments: Climate Change, Adaptive Restoration, and the Columbia River Basin. Seattle, WA: University of Washington Press. 232 pp. ISBN 978-0295747293.O’Gorman, Emily. 2021. Wetlands in a Dry Land: More-Than-Human-Histories of the Murray–Darling Basin. Seattle, WA: University of Washington Press. 288 pp. ISBN 978-0-295-74915-0.Styles, Megan. 2019. Roses from Kenya: Labor, Environment, and the Global Trade in Cut Flowers. Seattle, WA: University of Washington Press. 232 pp. ISBN 978-0-295-74650-0.Boyce, James K. 2019. The Case for Carbon Dividends. Medford, MA: Polity Press. 140 pp. ISBN 978-1-5095-2655-0.Rahder, Micha. 2020. An Ecology of Knowledges: Fear, Love, and Technoscience in Guatemalan Conservation. Durham, NC: Duke University Press. 316 pp. ISBN 978-1-4780-0691-6.Lewis, Simon L., and Mark A. Maslin. 2018. The Human Planet: How We Created the Anthropocene. New Haven, CT: Yale University Press. 496 pp. ISBN 978-0-241-28088-1.Braverman, Irus, and Elizabeth R. Johnson, eds. 2020. Blue Legalities: The Life & Laws of the Sea. Durham, NC: Duke University Press. 342 pp. ISBN 978-1-4780-0654-1.Chaney, Robert. 2020. The Grizzly in the Driveway: The Return of Bears to a Crowded American West. Seattle, WA: University of Washington Press. 288 pp. ISBN 978-0-295-74793-4.

Thomas Nagel’s 1974 essay “What Is It Like to Be a Bat?”[1] is one of the most cited texts on the problem of consciousness, and its theses have been discussed and debated in many different fields, from philosophy of mind to animal cognition and animal ethics. Nagel’s argument, that it is ultimately impossible for us to know what it is like to be a bat for a bat given the extreme differences in sensory experience between humans and bats, has come under fire from very different and even opposed perspectives: if, on the one hand, science-oriented philosophers and scholars accused him of underestimating and ultimately curtailing the power of scientific inquiry, on the other researchers in the humanities and animal ethics indicted him of defeatism for dismissing the power of imagination in bridging the species gap. In what follows, I will present and contrast two such positions, the critique of Nagel by neurophilosopher[2] Kathleen Akins and a very different approach to bat lives through poetry, exemplified by two poems by Ted Hughes (1930-1998) and Les Murray (1938-2019). The goal of counterposing these two different ways of looking at bats is not only or not much that of suggesting a preferable approach to bats’ otherness (though this is also what I will do), but also of emphasizing the aesthetic dimension of our relationship with the animal other and the role it plays in our ethical decision-making. [1] T. Nagel, “What Is It Like to Be a Bat?”, in The Philosophical Review, vol. 83, n. 4, 1974, pp. 435-450. [2] Neurophilosophy is an interdisciplinary field at the intersection of philosophy and the neurosciences in which traditional philosophical problems about the nature of the mind are approached through current findings within the neurosciences.

-Chuck Meide, Kathleen Deagan ,Columbus's outpost among the Taínos: Spain and America at La Isabela, 1493-1498. New Haven CT: Yale University Press, 2002. x + 294 pp., José María Cruxent (eds)-Lee D. Baker, George M. Fredrickson, Racism: A short history. Princeton NJ: Princeton University Press, 2002. x + 207 pp.-Evelyn Powell Jennings, Sherry Johnson, The social transformation of eighteenth-century Cuba. Gainesville: University Press of Florida, 2001. x + 267 pp.-Michael Zeuske, J.S. Thrasher, The island of Cuba: A political essay by Alexander von Humboldt. Translated from Spanish with notes and a preliminary essay by J.S. Thrasher. Princeton NJ: Markus Wiener; Kingston: Ian Randle, 2001. vii + 280 pp.-Matt D. Childs, Virginia M. Bouvier, Whose America? The war of 1898 and the battles to define the nation. Westport CT: Praeger, 2001. xi + 241 pp.-Carmelo Mesa-Lago, Antonio Santamaría García, Sin azúcar no hay país: La industria azucarera y la economía cubana (1919-1939). Seville: Consejo Superior de Investigaciones Científicas, Universidad de Sevilla y Diputación de Sevilla, 2001. 624 pp.-Charles Rutheiser, Joseph L. Scarpaci ,Havana: Two faces of the Antillean Metropolis. Chapel Hill: University of North Carolina Press, 2002. x + 437 pp., Roberto Segre, Mario Coyula (eds)-Thomas Neuner, Ottmar Ette ,Kuba Heute: Politik, Wirtschaft, Kultur. Frankfurt am Main, Germany: Vervuert, 2001. 863 pp., Martin Franzbach (eds)-Mark B. Padilla, Emilio Bejel, Gay Cuban nation. Chicago: University of Chicago Press, 2001. xxiv + 257 pp.-Mark B. Padilla, Kamala Kempadoo, Sun, sex, and gold: Tourism and sex work in the Caribbean. New York: Rowman & Littlefield, 1999. viii + 356 pp.-Jane Desmond, Susanna Sloat, Caribbean dance from Abakuá to Zouk: How movement shapes identity. Gainesville: University Press of Florida, 2002. xx + 408 pp.-Karen Fog Olwig, Nina Glick Schiller ,Georges woke up laughing: Long-distance nationalism and the search for home. Durham NC: Duke University Press, 2001. x + 324 pp., Georges Eugene Fouron (eds)-Karen Fog Olwig, Nancy Foner, From Ellis Island to JFK: New York's two great waves of immigration. Chelsea MI: Russell Sage Foundation, 2000. xvi + 334 pp.-Aviva Chomsky, Lara Putnam, The company they kept: Migrants and the politics of gender in Caribbean Costa Rica, 1870-1960. Chapel Hill: University of North Carolina Press, 2002. xi + 303 pp.-Rebecca B. Bateman, Rosalyn Howard, Black Seminoles in the Bahamas. Gainesville: University Press of Florida, 2002. xvii + 150 pp.-Virginia Kerns, Carel Roessingh, The Belizean Garífuna: Organization of identity in an ethnic community in Central America. Amsterdam: Rozenberg. 2001. 264 pp.-Nicole Roberts, Susanna Regazzoni, Cuba: una literatura sin fronteras / Cuba: A literature beyond boundaries. Madrid: Iberoamericana/Frankfurt am Main, Germany: Vervuert, 2001. 148 pp.-Nicole Roberts, Lisa Sánchez González, Boricua literature: A literary history of the Puerto Rican Diaspora. New York: New York University Press, 2001. viii + 216 pp.-Kathleen Gyssels, Ange-Séverin Malanda, Passages II: Histoire et pouvoir dans la littérature antillo-guyanaise. Paris: Editions du Ciref, 2002. 245 pp.-Sue N. Greene, Simone A. James Alexander, Mother imagery in the novels of Afro-Caribbean women. Columbia MO: University of Missouri Press, 2001. x + 215 pp.-Gert Oostindie, Aarón Gamaliel Ramos ,Islands at the crossroads: Politics in the non-independent Caribbean., Angel Israel Rivera (eds)-Katherine E. Browne, David A.B. Murray, Opacity: Gender, sexuality, race, and the 'problem' of identity in Martinique. New York: Peter Lang, 2002. xi + 188 pp.-James Houk, Kean Gibson, Comfa religion and Creole language in a Caribbean community. Albany: State University of New York Press, 2001. xvii + 243 pp.-Kelvin Singh, Frank J. Korom, Hosay Trinidad: Muharram performances in an Indo-Caribbean Diaspora.Philadelphia: University of Pennsylvania Press, 2003. viii + 305 pages.-Lise Winer, Kim Johnson, Renegades: The history of the renegades steel orchestra of Trinidad and Tobago. With photos by Jeffrey Chock. Oxford UK: Macmillan Caribbean Publishers, 2002. 170 pp.-Jerome Teelucksingh, Glenford Deroy Howe, Race, war and nationalism: A social history of West Indians in the first world war. Kingston: Ian Randle/Oxford UK: James Currey, 2002. vi + 270 pp.-Geneviève Escure, Glenn Gilbert, Pidgin and Creole linguistics in the twenty-first century. New York: Peter Lang Publishing, 2002. 379 pp.-George L. Huttar, Eithne B. Carlin ,Atlas of the languages of Suriname. Leiden, The Netherlands: KITLV Press/Kingston: Ian Randle, 2002. vii + 345 pp., Jacques Arends (eds)

Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPi) have demonstrated efficacy in treating solid tumors with Homologous Recombination Deficiency (HRD), the inability to repair DNA double-stranded breaks through the Homologous Recombination Repair (HRR) pathway. Specific genetic and epigenetic alterations result in defective HRR function. Bi-allelic loss of BRCA1 or BRCA2 principally drives HRR deficiency. While BRCA1/2 are instrumental to HRR, multiple genes, including PALB2, impact the HRR pathway. PALB2 mutations occur in an estimated 0.97% to 3.66% of solid tumors [AACR GENIE PALB2] and are associated with susceptibility to various cancers. No clinically approved therapies specifically targeting PALB2 currently exist. Emerging evidence suggests that patients with germline or somatic PALB2 mutations may benefit from PARPi treatment, which has potential to be a new tumor agnostic therapy option across a wide range of solid tumors. Methods PAVO is a pan-tumor, single-arm, multicenter Phase-II study assessing the safety and efficacy of niraparib (a PARPi) in patients who harbor a confirmed PALB2 mutation. The study plans to enroll up to 110 adult subjects. Eligible participants must have: locally advanced or metastatic solid tumor(s); confirmed pathogenic or likely pathogenic somatic or germline PALB2 mutation; received all standard of care (SOC) therapy for their tumor type, or are unlikely to derive benefit from SOC therapy in the opinion of the treating physician; ECOG performance status of 0 or 1; life expectancy of ≥ 12 weeks with adequate organ/bone marrow function. Exclusion criteria include a confirmed somatic or germline BRCA1/2 mutation, prior treatment with any PARPi, ovarian or prostate cancer, or rapid progression while on platinum-based therapy in the metastatic setting. Niraparib will be administered in 28 day cycles with daily dosing, as outlined in the protocol. Participants will continue study treatment until documented radiographic progression, unacceptable toxicity, death, or consent withdrawal. The primary study endpoint is objective response rate (ORR), defined as the proportion of participants who have partial or complete response to therapy as assessed by Independent Central Review. Secondary endpoints include DOR, PFS, and CBR. PAVO is sponsored by Tempus with support from GSK (GlaxoSmithKline). The trial opened in March 2022. Tempus molecular data tracking (integrated NGS and EMR data) and the TIME Trial program (rapid match of patients to Just in TIME sites for clinical trials), enable patient identification and prescreening. Enrollment occurs through a combination of TIME and prospective clinical sites, where individualized prescreening models are in development. New site identification and referral of molecularly eligible patients to enrolling centers are ongoing. Clinical Trial Registry: NCT05169437 Citation Format: Tian Zhang, Thomas Weart, Matthias Weiss, Drew Murray, Minaxi Jhawer, Edward Huynh, Shumei Kato, Amy Cummings, Lydia Usha, Arvinder Bhinder, Rajiv Desai, Brad Johnson, Anjali Avadhani, Cecile Rose T. Vibat, Lauren Lopez, Brynna Driscoll, Annajane Ward, Christie K. Rice, Blathnaid Donovan, Scott Sherrin, Mykel Robble, Stephanie O'Leary, Kimberly Blackwell, Amine Aziez, Stephanie Petrone, Kathleen Harnden, Kimberly Strickland, Sonya Reid, Mark Robson, Andrew S. Paulson, Afshin Dowlati. PAVO: A phase-II, open label, single arm study of niraparib in patients with locally advanced/metastatic PALB2 mutated tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT055.

Abstract Metastatic breast cancer (MBC) remains incurable due to inevitable development of therapeutic resistance. Although tumor cell intrinsic mechanisms of resistance in MBC are beginning to be elucidated by bulk sequencing studies, the roles of the tumor microenvironment and intratumor heterogeneity in therapeutic resistance remain underexplored due to both technological barriers and limited availability of samples. To comprehensively capture these characteristics we have adapted a research biopsy protocol to collect tissue for an array of single-cell and spatio-molecular assays whose performance we have optimized for MBC, including single-cell and single-nucleus RNA sequencing, Slide-Seq, Multiplexed Error-Robust FISH (MERFISH), Expansion Sequencing (ExSEQ), Co-detection by Indexing (CODEX) and Multiplexed Ion Beam Imaging (MIBI). To date, we have successfully performed single-cell or single-nucleus RNAseq in 67 MBC biopsies and generated detailed accompanying clinical annotations for each. These samples provide a representation of the clinicopathological diversity of MBC including different breast cancer subtypes (44 HR+/HER2-, 3 HR-/HER2+, 3 HR+/HER2+, 16 TNBC, 1 unknown), common anatomic sites of metastasis (37 liver, 9 axilla, 7 breast, 5 bone, 3 chest wall, 3 neck, 1 brain, 1 lung, 1 skin), metastatic presentations (53 recurrent, 14 de novo) and histologic subtypes in the breast (45 IDC, 7 ILC, 6 mixed, 3 DCIS, 1 mucinous, 5 unknown/NA). Following optimization, both single-cell and single-nucleus RNA seq perform well in these MBC biopsies recovering all expected cell types including the malignant, stromal (e.g. fibroblasts, endothelial cells), myeloid (e.g. monocytes, macrophages) and lymphoid compartments (e.g. T cells, B cells, NK cells) as well as relevant oncogenic programs (e.g. cell cycle programs in all compartments; EMT-like and ER signaling programs in the malignant compartment, immune checkpoint programs in the lymphoid compartment; and fibroblast activation and vascular homeostasis programs in the stromal compartment). In addition to differences between the two techniques, these data demonstrate substantial intratumor heterogeneity in cell type composition. For example in liver biopsies the average number of cells per sample compartment by single nucleus RNA-seq was 6745 malignant (56%, SD 4216), 4637 stromal (41%, SD 3727), 1196 lymphoid (8%, SD 1617) and 874 myeloid (6%, SD 852); in breast biopsies the average number of cells per compartment by single nucleus RNA-seq was 6421 malignant (70%, SD 3497), 1628 stromal (24%, SD 117), 333 lymphoid (4%, SD 170) and 213 myeloid (3%, SD 117). Additionally, we find both inter- and intra-tumor heterogeneity in expression patterns and programs including, for example, expression of ER, PR and HER2 within clinical receptor subtypes (log normalized counts for ER expression in tumor cells by single cell RNA-seq: HR+/HER2- 0.921 (SD 0.714); HR+/HER2+ 0.768 (SD 0.624); HR-/HER2+ 0.018 (SD 0.122); and HR-/HER2- 0.005 (SD 0.066). For a subset of 13 biopsies we are also completing the spatiomolecular characterization methods on serial sections of a single adjacent biopsy. This unique experimental setup was designed to enable efficient comparison and integration of these assays. In spite of differences between experimental techniques and readouts, cell typing can be approached by annotation transfer from matching single cell or single nucleus RNAseq data, enabling exploratory analyses including evaluation of spatial phenotypes and cell type colocalization. Overall, these single cell and spatial data afford a comprehensive atlas including cell types, cell states/programs, cell interactions and spatial organization in MBC lesions. Future analyses will include serial biopsies over time and integration of clinicopathologic data including therapeutic response and resistance. Citation Format: Daniel L Abravanel, Johanna Klughammer, Timothy Blosser, Yury Goltsev, Sizun Jiang, Yunjao Bai, Evan Murray, Shahar Alon, Yi Cui, Daniel R Goodwin, Anubhav Sinha, Ofir Cohen, Michal Slyper, Orr Ashenberg, Danielle Dionne, Judit Jané-Valbuena, Caroline BM Porter, Asa Segerstolpe, Julia Waldman, Sébastien Vigneau, Karla Helvie, Allison Frangieh, Laura DelloStritto, Miraj Patel, Jingyi We, Kathleen Pfaff, Nicole Cullen, Ana Lako, Madison Turner, Isaac Wakiro, Sara Napolitano, Abhay Kanodia, Rebecca Ortiz, Colin MacKichan, Stephanie Inga, Judy Chen, Aaron R Thorner, Asaf Rotem, Scott Rodig, Fei Chen, Edward S Boyden, Garry P Nolan, Xiaowei Zhuang, Orit Rozenblatt-Rosen, Bruce E Johnson, Aviv Regev, Nikhil Wagle. Spatio-molecular dissection of the breast cancer metastatic microenvironment [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD6-03.

BackgroundUp to 70% of people with systemic sclerosis (SSc) report impaired physical function[1,2], which can negatively impact quality of life[3]. The Health Assessment Questionnaire Disability Index (HAQ DI) is a self-administered measure of function, where higher scores (range 0-3) indicate worse function.ObjectivesTo identify trajectories, clinical correlates and associations of functional disability in SSc.MethodsAustralian Scleroderma Cohort Study participants meeting ACR/EULAR criteria for SSc recruited within 5 years of SSc onset were included. Participants needed to have ≥2 HAQ DI scores available within 10 years of SSc onset. Group based trajectory modelling (GBTM) was used to identify the number and shape of HAQ DI score trajectories over 10 years. Between group comparisons were made using the chi-squared test for discrete variables and the two-sample t-test or Wilcoxon rank sum test for continuous variables. Generalised estimating equations were used to model longitudinal data involving repeated measures. Survival analyses were performed using Kaplan Meier and Cox proportional hazard modelling.Results426 participants were included with incident SSc and ≥2 HAQ DI scores, with median time between HAQ DI scores of 1.1 (IQR 1.0-1.4) years. Median age at SSc onset was 53 years (IQR 44-61 years), 83% were female and 33% had dcSSc.We found two HAQ DI trajectory groups: low/stable disability (n=221, 52%), and high/increasing disability (n=205, 48%; Figure 1). Participants with high/increasing disability were older (p=0.01) and more likely to have dcSSc (p<0.01), PAH (p<0.01) and multiple cardiovascular risk factors (p<0.01; Table 1). High/increasing disability was associated with markers of poor hand function such as digital ulcers and synovitis (p<0.01), upper and lower GI involvement (both p<0.01) and proximal muscle weakness and atrophy (both p<0.001). Use of immunosuppression (p<0.001), including prednisolone (p<0.001), was more frequent in those with high/increasing disability.Those with high/increasing disability had worse survival after adjusting for age, sex, dcSSc, PAH and ischaemic heart disease (HR 1.9, 95% CI 1.0-3.8, p=0.05), as did those with increasing baseline HAQ DI scores (HR 1.8, 95%CI 1.2-2.7, p=0.01).ConclusionTwo trajectories of functional disability in SSc were identified. Those with poorer function had a distinct clinical phenotype and survival compared to those with less functional disability. Further work is required to identify if amelioration of disease-specific features associated with higher HAQ DI scores results in a commensurate improvement in physical function.References[1]Zaghlol RS, Dawa GA, Makarm WK. Functional Disability Among Systemic Sclerosis Patients: Relation to Disease Characteristics and Quality of Life Parameters.Curr Rheumatol Rev2021.[2]Guillevin L, Hunsche E, Denton CP, et al. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry.Clin Exp Rheumatol2013;31(2 Suppl 76): 71-80.[3]Hossain S, Choudhury MR, Haque MM, Yeasmin S, Hossain F, Zaman MM. Functional disability and health-related quality of life among systemic sclerosis patients in Bangladesh.BMC Rheumatol2022;6(1): 60.Figure 1: Trajectory groupsTable 1: Clinical features and treatments in trajectory groupsVariableHigh/Increasing HAQ DI(N = 205)Low/Stable HAQ DI(N= 221)p-valueAge at SSc onset (y)56 (44-63)52 (41-59)<0.01DcSSc97 (47%)43 (20%)<0.01ANA Centromere64 (32%)104 (47%)<0.01Scl 7042 (21%)32 (15%)0.09IHD32 (16%)15 (7%)<0.01HTN126 (62%)85 (39%)<0.01PAH22 (11%)8 (4%)<0.01ILD78 (63%)54 (69%)0.358Digital ulcers117 (57%)90 (41%)<0.01Synovitis118 (58%)89 (40%)<0.01Proximal weakness75 (37%)31 (14%)<0.01Muscle atrophy64 (31%)24 (11%)<0.01Upper GI symptoms196 (96%)193 (87%)<0.01Lower GI symptoms188 (92%)175 (79%)<0.01Immunosuppression165 (81%)121 (55%)<0.01Prednisolone126 (62%)81 (37%)<0.01AcknowledgementsJLF holds a NHMRC Postgraduate Scholarship (GNT2013842) and an Australian Government Research Training Program Scholarship. LR holds an Arthritis Australia – ARA Victoria Fellowship. MN holds an NHMRC Investigator Grant (GNT1176538). KB holds an NHMRC Investigator Grant (GNT1197169).Disclosure of InterestsJessica Fairley Speakers bureau: Boerhinger Ingelheim, Dylan Hansen: None declared, Murray Baron: None declared, Susanna Proudman Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, Jo-Anne Sahhar Speakers bureau: Boehringer Ingelheim, Gene-Siew Ngian: None declared, Jenny Walker Speakers bureau: Boehringer Ingelheim, Lauren Host: None declared, Kathleen Morrisroe: None declared, Wendy Stevens Consultant of: Boehringer Ingelheim, Laura Ross: None declared, Mandana Nikpour Speakers bureau: Janssen, Boehringer Ingelheim, GSK, Consultant of: Janssen, Boehringer Ingelheim, Astra Zeneca, GSK.